In a series of strategic moves, Sanofi has been involved in numerous acquisitions and partnerships, aiming to enhance their focus on immunology and rare diseases. The multinational pharmaceutical company announced plans to acquire Blueprint Medicines for up to $9.5 billion. This aggressive push into the specialty-drug market is aimed at broadening Sanofi's pipeline in the lucrative oncology sector. In addition to Blueprint, Sanofi will acquire Vigil Neuroscience for an upfront $470 million, regardless of Vigil's recent setback in a Phase 2 study. The deal is eyed as a potential help in improving Sanofi's neurological pipeline.
The drugmaker also unveiled a commitment to invest $20 billion within the US through 2030, enlarging its footprint in a key market. Sanofi also partners with local manufacturers to explore vaccine production possibilities in Vietnam. However, the company dealt with mixed results in key trials, especially pertaining to a drug designed to treat COPD, jointly developed with Regeneron, dragging its stock lower.
Sanofi News Analytics from Fri, 07 Mar 2025 08:00:00 GMT to Sat, 07 Jun 2025 14:00:00 GMT - Rating 0 - Innovation 8 - Information 10 - Rumor -2
